A5039070318- Angiogenesis and VEGF in Cancer
- Cell Adhesion Molecules Research
- Ferroptosis and cancer prognosis
- Heat shock proteins research
- RNA Research and Splicing
- Hippo pathway signaling and YAP/TAZ
- Lymphatic System and Diseases
- Caveolin-1 and cellular processes
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Cellular Mechanics and Interactions
- Cancer Immunotherapy and Biomarkers
University of Massachusetts Chan Medical School
2022-2024
Prostate cancers are largely unresponsive to immune checkpoint inhibitors (ICIs), and there is strong evidence that programmed death-ligand 1 (PD-L1) expression itself must be inhibited activate antitumor immunity. Here, we report neuropilin-2 (NRP2), which functions as a vascular endothelial growth factor (VEGF) receptor on tumor cells, an attractive target immunity in prostate cancer because VEGF-NRP2 signaling sustains PD-L1 expression. NRP2 depletion increased T cell activation vitro. In...
Although the immune checkpoint function of PD-L1 has dominated its study, we report that an unanticipated intrinsic in promoting dynamics persistent cell migration. concentrates at rear migrating carcinoma cells where it facilitates retraction, resulting formation PD-L1–containing retraction fibers and migrasomes. promotes by interacting with localizing β4 integrin to enabling this stimulate contractility. This mechanism involves ability maintain polarity lower membrane tension compared...
Understanding the cell biological mechanisms that enable tumor cells to persist after therapy is necessary improve treatment of recurrent disease. Here, we demonstrate transient receptor potential channel 6 (TRPC6), a mediates calcium entry, contributes properties breast cancer stem cells, including resistance chemotherapy, and are dependent on TRPC6. The mechanism involves ability TRPC6 regulate integrin α6 mRNA splicing. Specifically, TRPC6-mediated entry represses epithelial splicing...
Abstract Prostate cancers (PC) are largely unresponsive to immune checkpoint inhibitors and there is strong evidence that PD-L1 expression itself must be inhibited activate anti-tumor immunity. Here, we report neuropilin-2 (NRP2), which functions as a VEGF receptor on tumor cells, an attractive target immunity in prostate cancer because demonstrate VEGF/NRP2 signaling sustains expression. NRP2 depletion increased T cell activation vitro immune-mediated elimination vivo using humanized mouse...